Richtig G, Wolf M, Schulter G, et al. Body-Mass-Index as a predictive marker for response in patients with metastatic melanoma treated with ipilimumab. SMR 2017, P01-15.
BO-112 plus pembrolizumab bij anti-PD-1-resistent gevorderd melanoom
aug 2025 | Dermato-oncologie, Immuuntherapie